FGF-23 Suppressibility by Calcitonin
This study is currently recruiting participants.
Verified August 2011 by Rijnstate Hospital
Sponsor:
Rijnstate Hospital
Information provided by:
Rijnstate Hospital
ClinicalTrials.gov Identifier:
NCT00688077
First received: May 28, 2008
Last updated: August 8, 2011
Last verified: August 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Introduction:
Based on our experience with calcitonin as an FGF-23 suppressive agent in a patient with an FGF-23 producing tumor we hypothesize that calcitonin may be a physiologically important regulator of FGF-23 production and secretion in healthy humans.
Aim:
In this study we wish to examine the FGF-23 suppressive effects of calcitonin in healthy men.
Study Design:
placebo-controlled, cross-over study
Method:
- All twelve subjects are examined on two occasions, once after exposure to placebo 1 ml NaCl 0.9% subcutaneously, and once following calcitonin 200 IU/ml subcutaneously
- On both occasions frequent bloodsampling will take place, out an indwelling catheter in de forearm vein.
- Sampling times: -15, 0, 60, 120, 240, 360, and 480 minutes
- Mealtimes: Calcium and Phosphate intake standardized on both occasions
- All samples are analyzed for FGF-23, using a C-terminal FGF-23 ELISA kit (Immunotopics, San Clemente, USA) that measures intact and C-terminal fragments of FGF-23, and one that measures only intact FGF-23
- Samples obtained at T-15, T0, T240 and T480 are stored for later analysis of Ca, albumin, PO4, PTH, 25-OHD and 1,25-OHD
Endpoint:
A change of 25% in de serum FGF-23 levels in response to a single subcutaneous injection of calcitonin 200 IU.
| Condition | Intervention |
|---|---|
|
Hypophosphatemia |
Drug: Calcitonin Drug: Placebo |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Single Blind (Subject) Primary Purpose: Basic Science |
| Official Title: | Evaluation of FGF-23 Suppressibility by Calcitonin in Healthy Men - Pilot Study |
Resource links provided by NLM:
Further study details as provided by Rijnstate Hospital:
Primary Outcome Measures:
- A change of 25% in de serum FGF-23 levels in response to a single subcutaneous injection of calcitonin 200 IU. [ Time Frame: eight hours ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 12 |
| Study Start Date: | May 2008 |
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 |
Drug: Calcitonin
Calcitonin 200 IU/ml, single subcutaneous injection, experimental group
|
|
Placebo Comparator: 2
NaCl 0,9% 2 ml, single subcutaneous injection
|
Drug: Placebo
NaCl 0,9 % 1ml, single subcutaneous injection, placebo group
|
Eligibility| Ages Eligible for Study: | 20 Years to 55 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Healthy man, who are between 20-55 years old, and have a BMI 20-27 kg/m2.
Exclusion Criteria:
- Serum creatinin >100 mmol/L, or glomerular filtration rate <80 ml/min.
- Abnormal serum Ca, PO4, albumin, 25-OH vitamin D, or PTH levels.
- Any medication.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00688077
Contacts
| Contact: Hans Boer de, MD, PhD | 31-2-6378-8888 | hdeboer@alysis.nl |
| Contact: Carmen Horjus, MD | chthorje@alysis.nl |
Locations
| Netherlands | |
| Rijnstate Hospital | Recruiting |
| Arnhem, Gelderland, Netherlands | |
| Principal Investigator: Hans Boer de, MD, PhD | |
Sponsors and Collaborators
Rijnstate Hospital
More Information
No publications provided
| Responsible Party: | H. de Boer MD. PhD., Rijnstate Hospital, Arnhem |
| ClinicalTrials.gov Identifier: | NCT00688077 History of Changes |
| Other Study ID Numbers: | LTC-524/030408 |
| Study First Received: | May 28, 2008 |
| Last Updated: | August 8, 2011 |
| Health Authority: | Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
Keywords provided by Rijnstate Hospital:
|
Fibroblast growth factor - 23 Calcitonin |
Additional relevant MeSH terms:
|
Hypophosphatemia Phosphorus Metabolism Disorders Metabolic Diseases Salmon calcitonin Calcitonin Calcitonin Gene-Related Peptide |
Bone Density Conservation Agents Physiological Effects of Drugs Pharmacologic Actions Vasodilator Agents Cardiovascular Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on June 18, 2013